We are pleased to inform our stakeholders that GE Healthcare has confirmed a sufficient inventory of Sulfur Colloid to last through the end of June. The company is in the process of transitioning to a new supplier for the active pharmaceutical ingredient. This transition has necessitated the temporary allocation of Sulfur Colloid supplies. This is a precautionary measure aimed at effectively managing our stock during this period of change.
To ensure equitable distribution and continuity of supply to all laboratories, allocation has been determined based on historical shipment levels. GE Healthcare is committed to maintaining a steady supply and expects to release the new batch of Sulfur Colloid by the end of May.
The current listing of Sulfur Colloid on the Health Canada website is part of the regulatory requirements associated with the supplier transition. It is important to note that this listing does not signify a shortage. GE Healthcare plans to remove Sulfur Colloid from the drug shortage list by the end of this month.
To date, we have not received any reports from laboratories concerning reduced volumes of Sulfur Colloid. We acknowledge the importance of consistent supply, especially given recent challenges in the healthcare sector. We will continue to monitor the situation closely and maintain open lines of communication with GE Healthcare.
We are committed to keeping you informed with any updates or changes. Should you have any concerns or require further details, please do not hesitate to contact us. Your cooperation and understanding are greatly appreciated as we navigate these temporary adjustments.
